12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

HRS7-SN-38 regulatory update

FDA granted Orphan Drug designation to IMMU-132 to treat small cell lung cancer (SCLC). In October, Immunomedics said it expanded a Phase I trial evaluating IMMU-132 in patients...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >